Part 1 of 3: Beyond the Joint: The Burden and Biology of Uncontrolled Gout

Managing uncontrolled gout can be challenging, especially when patients continue to flare, struggle with comorbidities, or fail to respond as expected to standard therapy. As the understanding of gout evolves beyond hyperuricemia alone, clinicians are increasingly called upon to integrate immune mechanisms, real-world evidence, and new treatment options into everyday decision-making. Staying current requires not only awareness of emerging data, but also clarity on how to apply it in complex, real-world patients. From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026 is a CME-accredited educational program designed to help clinicians navigate these challenges with confidence. This program brings together expert perspectives, recent clinical evidence, and practical insights across the continuum of gout care. Learners will explore advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted approaches, while also addressing safety, sequencing, and multidisciplinary coordination. Through focused discussion and clinically relevant examples, participants will gain actionable strategies to personalize care, overcome treatment inertia, and improve long-term management for patients living with uncontrolled gout.